<DOC>
	<DOCNO>NCT00631371</DOCNO>
	<brief_summary>Primary objective : Comparison independently assess progression free survival ( PFS ) subject administer Bevacizumab + Temsirolimus vs. administer Bevacizumab + Interferon-Alfa . Secondary objective : safety , Investigator assess PFS , objective response rate ( independently assess ) , overall survival .</brief_summary>
	<brief_title>Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Histologically and/or cytologically confirm advanced renal cell carcinoma ( RCC ) Majority component conventional clearcell type mandatory At least 1 measurable lesion ( per RECIST ) Prior systemic treatment RCC Evidence current prior central nervous system ( CNS ) metastases Cardiovascular disease Pregnant nursing woman Additional criterion applies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>temsirolimus</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>kidney cancer</keyword>
	<keyword>urogenital cancer</keyword>
</DOC>